Profile data is unavailable for this security.
About the company
Radiopharm Theranostics Limited is an Australia-based clinical-stage radiotherapeutics company developing a platform of radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The Company has a pipeline of highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase II and three Phase I trials in a variety of solid tumor cancers including lung, breast, and brain. Its technologies include Nano-mAbs, Pivalate, AVB6 Integrin, PSA-mAb, and PTPu. Nano-mAbs is a novel radiopharmaceutical platform made using genetic engineered camelid derived single domain antibodies (sdAb) labelled with a radioisotope of therapeutic radiation. Pivalate is an 18F-FPIA radiotracer, based on a short chain carbohydrate which utilizes the early steps of fatty acid oxidation.
- Revenue in AUD (TTM)3.63m
- Net income in AUD-38.34m
- Incorporated2021
- Employees14.00
- LocationRadiopharm Theranostics LtdLevel 3, 62 Lygon Street, CarltonMELBOURNE 3053AustraliaAUS
- Phone+61 39824-5254
- Websitehttps://radiopharmtheranostics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vitura Health Ltd | 124.04m | 3.28m | 28.50m | 119.00 | 7.96 | 0.5908 | 5.37 | 0.2298 | 0.0054 | 0.0054 | 0.2034 | 0.0728 | 1.69 | 16.43 | 10.46 | -- | 4.11 | 12.75 | 5.72 | 17.62 | 27.21 | 30.97 | 2.43 | 6.06 | 1.05 | 9.50 | 0.2009 | -- | 0.1341 | 298.23 | -5.35 | -- | 129.38 | -- |
| Little Green Pharma Ltd | 38.49m | 5.86m | 32.09m | -- | 5.43 | 0.3731 | 3.31 | 0.8337 | 0.0194 | 0.0194 | 0.1268 | 0.2814 | 0.4262 | 0.8199 | 14.01 | -- | 6.48 | -- | 7.09 | -- | 67.46 | -- | 15.21 | -- | 0.8728 | -4.71 | 0.0541 | -- | 43.67 | -- | 140.77 | -- | -- | -- |
| TrivarX Ltd | 1.13m | -943.23k | 32.30m | 4.00 | -- | 1.37 | -- | 28.52 | -0.0018 | -0.0018 | 0.0023 | 0.0204 | 0.0923 | -- | -- | -- | -7.68 | -33.47 | -8.32 | -37.46 | -- | -- | -83.27 | -373.85 | -- | -27.05 | 0.0132 | -- | 26.38 | 3.89 | 34.25 | -- | 6.29 | -- |
| Avecho Biotechnology Ltd | 1.38m | -3.62m | 33.06m | 29.00 | -- | 34.61 | -- | 23.95 | -0.0011 | -0.0011 | 0.0004 | 0.0003 | 0.2115 | 4.46 | 1.91 | -- | -55.49 | -61.23 | -72.92 | -73.27 | 62.27 | 55.45 | -262.41 | -382.04 | 4.53 | -8.03 | 0.0647 | -- | 139.19 | -23.20 | 9.15 | -- | -- | -- |
| Inoviq Ltd | 916.53k | -7.24m | 49.27m | 85.00 | -- | 2.21 | -- | 53.76 | -0.0615 | -0.0615 | 0.0078 | 0.1581 | 0.0401 | 3.61 | 0.9209 | -- | -31.68 | -43.01 | -34.39 | -45.87 | 86.76 | 89.08 | -789.61 | -1,543.44 | 7.54 | -- | 0.012 | -- | 21.17 | 57.69 | -5.77 | -- | -- | -- |
| Medical Developments International Ltd | 40.64m | -436.00k | 50.13m | 68.00 | -- | 0.9154 | 19.77 | 1.23 | -0.0039 | -0.0039 | 0.3608 | 0.4862 | 0.6306 | 1.30 | 5.32 | -- | -0.6765 | -16.68 | -0.7455 | -18.92 | 75.19 | 72.70 | -1.07 | -47.08 | 4.54 | -- | 0.0324 | -- | 17.82 | 11.30 | 100.23 | -24.33 | -34.91 | -- |
| Neurizon Therapeutics Ltd | 1.88m | -16.59m | 63.35m | 52.00 | -- | 16.33 | -- | 33.66 | -0.0334 | -0.0334 | 0.0038 | 0.0056 | 0.2431 | -- | 203.57 | -- | -214.34 | -65.69 | -254.22 | -74.86 | -- | -- | -881.68 | -368.00 | -- | -- | 0.00 | -- | -- | -- | -86.45 | -- | -44.79 | -- |
| Radiopharm Theranostics Ltd | 3.63m | -38.34m | 81.52m | 14.00 | -- | 1.21 | -- | 22.44 | -0.0179 | -0.0179 | 0.0017 | 0.0189 | 0.0458 | -- | 0.6382 | 259,530.70 | -48.38 | -- | -59.58 | -- | 1.08 | -- | -1,055.27 | -- | -- | -7.52 | 0.00 | -- | 1,114.26 | -- | 20.04 | -- | -- | -- |
| Biome Australia Ltd | 18.49m | 214.66k | 93.50m | 30.00 | 451.61 | 19.82 | 204.75 | 5.06 | 0.0009 | 0.0009 | 0.0833 | 0.0212 | 1.83 | 2.39 | 5.14 | -- | 2.12 | -43.09 | 5.42 | -74.65 | 61.27 | 60.84 | 1.16 | -31.29 | 1.02 | 1.80 | 0.3966 | -- | 41.43 | 80.32 | 112.85 | -- | 2.18 | -- |
| Botanix Pharmaceuticals Ltd | 5.76m | -86.40m | 124.21m | 1.00 | -- | 1.35 | -- | 21.58 | -0.0466 | -0.0466 | 0.0031 | 0.0415 | 0.0477 | 0.2477 | 3.48 | -- | -71.53 | -50.27 | -81.16 | -56.02 | 36.99 | -- | -1,500.65 | -1,888.17 | 2.87 | -- | 0.2226 | -- | 856.64 | 102.14 | -522.91 | -- | 63.43 | -- |
| Vita Life Sciences Ltd | 93.27m | 10.44m | 145.84m | 124.00 | 14.56 | 2.63 | -- | 1.56 | 0.1833 | 0.1833 | 1.64 | 1.01 | 1.21 | 2.29 | 7.28 | -- | 13.52 | 15.15 | 18.79 | 21.21 | 61.15 | 59.76 | 11.18 | 11.85 | 2.10 | -- | 0.0409 | 57.39 | 17.31 | 14.95 | 18.80 | 11.36 | 44.98 | 26.93 |
| Recce Pharmaceuticals Ltd | 7.70m | -21.43m | 156.16m | -- | -- | -- | -- | 20.27 | -0.0899 | -0.0899 | 0.0325 | -0.0106 | 0.8203 | -- | 25.91 | -- | -228.15 | -150.15 | -- | -318.01 | -- | -- | -278.12 | -340.57 | -- | -17.98 | 1.49 | -- | 47.14 | 46.35 | -21.33 | -- | 34.71 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Regal Funds Management Pty Ltd.as of 31 Dec 2025 | 293.42m | 8.28% |
